1.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
2.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAP001, PDDG/CAP001, NCT00854477
|
|
3.
|
Phase: Phase IV
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-085, NCT00920023
|
|
4.
|
Phase: Phase IV
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0487, NCT00966277
|
|
5.
|
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: Steel vs nitinol, NCT00980889
|
|
6.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 07-0585-AE, Protocol# in Pfizer: GA30517W, NCT00937508
|
|
7.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 005/2008, NCT01015170
|
|
8.
|
Phase: Phase IV
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MD-095-PP-05A, NCT00495352
|
|
9.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 16 to 45
Sponsor: Other
Protocol IDs: P50DA016511, NCT00664755
|
|
10.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2009-P-000444, NCT00907218
|
|
11.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RaMM-BO 2.0, NCT01041612
|
|
12.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
|
|
13.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: AMC0183, NCT00689715
|
|
15.
|
Phase: Phase III, Phase II
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: NNR-02, NCT00753441
|
|
16.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SRSI-PACT-7, PACT-7, EU-20932, NCT00960284
|
|
17.
|
Phase: Phase III, Phase II
Type: Behavioral study, Prevention
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: NURA-001-09S, NCT00960375
|
|
18.
|
Phase: Phase III, Phase II
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NIDA-16427-5, R01-16427-5, DPMC, NCT00132821
|
|
19.
|
Phase: Phase III, Phase II
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 to 65
Sponsor: NCI, Other
Protocol IDs: 2003-1024, 1R01DA017073, NCT00507728
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GV-001.004, NCT00051467
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CRUK-TELOVAC-V4, EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
|
|
22.
|
Phase: Phase III
Type: Health services research
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SWS-SAKK-95/06, SAKK-95/06, EU-20711, SWS-SAKK-E-MOSAIC, NCT00477919
|
|
23.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 06.23.CLI, NCT00455247
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TASMC-07-NA-132-CTIL, NCT00486460
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IPC-BAYPAN, BAYPAN, INCA-RECF0426, IPC-2005-006, NCT00541021
|
